Trials / Completed
CompletedNCT00277160
A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 852 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess pegfilgrastim starting with the first cycle versus secondary prophylaxis on neutropenic events (including neutropenia +/- fever, dose delays, dose reductions, and hospitalizations) in older patients receiving chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neulasta (pegfilgrastim) | Commercial pegfilgrastim 6mg single subcutaneous fixed-dose |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2004-11-01
- Completion
- 2005-01-01
- First posted
- 2006-01-16
- Last updated
- 2010-10-08
Source: ClinicalTrials.gov record NCT00277160. Inclusion in this directory is not an endorsement.